Propanc Biopharma Inc (NASDAQ:PPCB) Short Interest Down 94.9% in May

Propanc Biopharma Inc (NASDAQ:PPCB) was the target of a large decrease in short interest during the month of May. As of May 29th, there was short interest totaling 31,201 shares, a decrease of 94.9% from the May 14th total of 617,010 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average trading volume of 90,333 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Propanc Biopharma Stock Performance

PPCB traded up $0.01 during mid-day trading on Tuesday, reaching $1.38. The stock had a trading volume of 34,431 shares, compared to its average volume of 64,720. The stock has a market capitalization of $3.15 million, a P/E ratio of -0.06 and a beta of 3.48. The firm’s fifty day simple moving average is $2.30 and its two-hundred day simple moving average is $7.50. Propanc Biopharma has a 52 week low of $1.31 and a 52 week high of $270.25.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Propanc Biopharma stock. Virtu Financial LLC purchased a new position in Propanc Biopharma Inc (NASDAQ:PPCB) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned about 0.33% of Propanc Biopharma as of its most recent SEC filing.

About Propanc Biopharma

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.